Bryan, Garnier & Co reaffirmed their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Monday morning. Bryan, Garnier & Co currently has a GBX 5,220 ($63.62) target price on the biopharmaceutical company’s stock.
Several other analysts also recently commented on the stock. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,600 ($68.25) target price on shares of AstraZeneca plc in a report on Thursday, June 30th. Citigroup Inc. reaffirmed a buy rating on shares of AstraZeneca plc in a report on Thursday, June 23rd. Societe Generale reaffirmed a buy rating and set a GBX 6,900 ($84.10) target price on shares of AstraZeneca plc in a report on Friday, June 24th. Berenberg Bank boosted their price objective on shares of AstraZeneca plc from GBX 4,950 ($60.33) to GBX 5,400 ($65.81) and gave the company a buy rating in a report on Tuesday, July 12th. Finally, BNP Paribas set a GBX 5,300 ($64.59) price objective on shares of AstraZeneca plc and gave the company a buy rating in a report on Tuesday, August 2nd. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of GBX 4,960.13 ($60.45).
AstraZeneca plc (LON:AZN) opened at 5027.00 on Monday. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The firm’s 50-day moving average is GBX 4,994.82 and its 200-day moving average is GBX 4,488.47. The company’s market cap is GBX 63.59 billion.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.